 | • レポートコード：MRC23Q36424 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥406,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥812,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のα-1治療市場について調査・分析し、世界のα-1治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他）、用途別セグメント分析（病院、専門クリニック、薬局）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、GlaxoSmithKline、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical Industries、Takeda、Baxter、Grifols、CSL Behring、Kamada Ltd、Chiesi Pharmaceuticals、Kedrion Group、Vertex Pharmaceuticals、ProMetic Life Sciencesなどが含まれています。世界のα-1治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、α-1治療市場規模を推定する際に考慮しました。本レポートは、α-1治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、α-1治療に関するビジネス上の意思決定に役立てることを目的としています。 ・α-1治療市場の概要 - α-1治療のタイプ別セグメント - 世界のα-1治療市場規模：タイプ別分析（増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他） - α-1治療の用途別セグメント - 世界のα-1治療市場規模：用途別分析（病院、専門クリニック、薬局） - 世界のα-1治療市場規模予測（2018年-2029年） ・α-1治療市場の成長トレンド - α-1治療の地域別市場規模（2018年-2029年） - α-1治療市場ダイナミクス - α-1治療の業界動向 - α-1治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他 - 世界のα-1治療のタイプ別市場規模（2018年-2023年） - 世界のα-1治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、専門クリニック、薬局 - 世界のα-1治療の用途別市場規模（2018年-2023年） - 世界のα-1治療の用途別市場規模（2024年-2029年） ・α-1治療の地域別市場規模 - 北米のα-1治療市場規模（2018年-2029年） - アメリカのα-1治療市場規模（2018年-2029年） - ヨーロッパのα-1治療市場規模（2018年-2029年） - アジア太平洋のα-1治療市場規模（2018年-2029年） - 中国のα-1治療市場規模（2018年-2029年） - 日本のα-1治療市場規模（2018年-2029年） - 韓国のα-1治療市場規模（2018年-2029年） - インドのα-1治療市場規模（2018年-2029年） - オーストラリアのα-1治療市場規模（2018年-2029年） - 中南米のα-1治療市場規模（2018年-2029年） - 中東・アフリカのα-1治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer、GlaxoSmithKline、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical Industries、Takeda、Baxter、Grifols、CSL Behring、Kamada Ltd、Chiesi Pharmaceuticals、Kedrion Group、Vertex Pharmaceuticals、ProMetic Life Sciences ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Treatments for Alpha-1 market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Treatments for Alpha-1 is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Treatments for Alpha-1 is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Treatments for Alpha-1 in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Treatments for Alpha-1 include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols and CSL Behring, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Treatments for Alpha-1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Treatments for Alpha-1.
The Treatments for Alpha-1 market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Treatments for Alpha-1 market comprehensively. Regional market sizes, concerning products by indication, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Treatments for Alpha-1 companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by indication, by application, and by regions.
By Company
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Segment by Application
Hospitals
Specialty Clinics
Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by indication, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Treatments for Alpha-1 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Indication
1.2.1 Global Treatments for Alpha-1 Market Size Growth Rate by Indication: 2018 VS 2022 VS 2029
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
1.3 Market by Application
1.3.1 Global Treatments for Alpha-1 Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Treatments for Alpha-1 Market Perspective (2018-2029)
2.2 Treatments for Alpha-1 Growth Trends by Region
2.2.1 Global Treatments for Alpha-1 Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Treatments for Alpha-1 Historic Market Size by Region (2018-2023)
2.2.3 Treatments for Alpha-1 Forecasted Market Size by Region (2024-2029)
2.3 Treatments for Alpha-1 Market Dynamics
2.3.1 Treatments for Alpha-1 Industry Trends
2.3.2 Treatments for Alpha-1 Market Drivers
2.3.3 Treatments for Alpha-1 Market Challenges
2.3.4 Treatments for Alpha-1 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Treatments for Alpha-1 Players by Revenue
3.1.1 Global Top Treatments for Alpha-1 Players by Revenue (2018-2023)
3.1.2 Global Treatments for Alpha-1 Revenue Market Share by Players (2018-2023)
3.2 Global Treatments for Alpha-1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Treatments for Alpha-1 Revenue
3.4 Global Treatments for Alpha-1 Market Concentration Ratio
3.4.1 Global Treatments for Alpha-1 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Treatments for Alpha-1 Revenue in 2022
3.5 Treatments for Alpha-1 Key Players Head office and Area Served
3.6 Key Players Treatments for Alpha-1 Product Solution and Service
3.7 Date of Enter into Treatments for Alpha-1 Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Treatments for Alpha-1 Breakdown Data by Indication
4.1 Global Treatments for Alpha-1 Historic Market Size by Indication (2018-2023)
4.2 Global Treatments for Alpha-1 Forecasted Market Size by Indication (2024-2029)
5 Treatments for Alpha-1 Breakdown Data by Application
5.1 Global Treatments for Alpha-1 Historic Market Size by Application (2018-2023)
5.2 Global Treatments for Alpha-1 Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Treatments for Alpha-1 Market Size (2018-2029)
6.2 North America Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Treatments for Alpha-1 Market Size by Country (2018-2023)
6.4 North America Treatments for Alpha-1 Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Treatments for Alpha-1 Market Size (2018-2029)
7.2 Europe Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Treatments for Alpha-1 Market Size by Country (2018-2023)
7.4 Europe Treatments for Alpha-1 Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Treatments for Alpha-1 Market Size (2018-2029)
8.2 Asia-Pacific Treatments for Alpha-1 Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Treatments for Alpha-1 Market Size by Region (2018-2023)
8.4 Asia-Pacific Treatments for Alpha-1 Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Treatments for Alpha-1 Market Size (2018-2029)
9.2 Latin America Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Treatments for Alpha-1 Market Size by Country (2018-2023)
9.4 Latin America Treatments for Alpha-1 Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Treatments for Alpha-1 Market Size (2018-2029)
10.2 Middle East & Africa Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Treatments for Alpha-1 Market Size by Country (2018-2023)
10.4 Middle East & Africa Treatments for Alpha-1 Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Treatments for Alpha-1 Introduction
11.1.4 Pfizer Revenue in Treatments for Alpha-1 Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Treatments for Alpha-1 Introduction
11.2.4 GlaxoSmithKline Revenue in Treatments for Alpha-1 Business (2018-2023)
11.2.5 GlaxoSmithKline Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Treatments for Alpha-1 Introduction
11.3.4 AstraZeneca Revenue in Treatments for Alpha-1 Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Treatments for Alpha-1 Introduction
11.4.4 Boehringer Ingelheim Revenue in Treatments for Alpha-1 Business (2018-2023)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Treatments for Alpha-1 Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Treatments for Alpha-1 Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Treatments for Alpha-1 Introduction
11.6.4 Takeda Revenue in Treatments for Alpha-1 Business (2018-2023)
11.6.5 Takeda Recent Development
11.7 Baxter
11.7.1 Baxter Company Detail
11.7.2 Baxter Business Overview
11.7.3 Baxter Treatments for Alpha-1 Introduction
11.7.4 Baxter Revenue in Treatments for Alpha-1 Business (2018-2023)
11.7.5 Baxter Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Treatments for Alpha-1 Introduction
11.8.4 Grifols Revenue in Treatments for Alpha-1 Business (2018-2023)
11.8.5 Grifols Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Detail
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Treatments for Alpha-1 Introduction
11.9.4 CSL Behring Revenue in Treatments for Alpha-1 Business (2018-2023)
11.9.5 CSL Behring Recent Development
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Detail
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Treatments for Alpha-1 Introduction
11.10.4 Kamada Ltd Revenue in Treatments for Alpha-1 Business (2018-2023)
11.10.5 Kamada Ltd Recent Development
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Detail
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Treatments for Alpha-1 Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2018-2023)
11.11.5 Chiesi Pharmaceuticals Recent Development
11.12 Kedrion Group
11.12.1 Kedrion Group Company Detail
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Treatments for Alpha-1 Introduction
11.12.4 Kedrion Group Revenue in Treatments for Alpha-1 Business (2018-2023)
11.12.5 Kedrion Group Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Detail
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Treatments for Alpha-1 Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2018-2023)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Detail
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Treatments for Alpha-1 Introduction
11.14.4 ProMetic Life Sciences Revenue in Treatments for Alpha-1 Business (2018-2023)
11.14.5 ProMetic Life Sciences Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details